DE69930416D1 - Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion - Google Patents

Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion

Info

Publication number
DE69930416D1
DE69930416D1 DE69930416T DE69930416T DE69930416D1 DE 69930416 D1 DE69930416 D1 DE 69930416D1 DE 69930416 T DE69930416 T DE 69930416T DE 69930416 T DE69930416 T DE 69930416T DE 69930416 D1 DE69930416 D1 DE 69930416D1
Authority
DE
Germany
Prior art keywords
sexual dysfunction
pde5 inhibitors
cgmp pde5
inhalation treatment
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69930416T
Other languages
English (en)
Other versions
DE69930416T2 (de
Inventor
Reto Naef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69930416D1 publication Critical patent/DE69930416D1/de
Application granted granted Critical
Publication of DE69930416T2 publication Critical patent/DE69930416T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69930416T 1998-12-22 1999-12-21 Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion Expired - Fee Related DE69930416T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828340.1A GB9828340D0 (en) 1998-12-22 1998-12-22 Organic compounds
GB9828340 1998-12-22
PCT/EP1999/010250 WO2000037061A2 (en) 1998-12-22 1999-12-21 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION

Publications (2)

Publication Number Publication Date
DE69930416D1 true DE69930416D1 (de) 2006-05-11
DE69930416T2 DE69930416T2 (de) 2006-11-02

Family

ID=10844812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930416T Expired - Fee Related DE69930416T2 (de) 1998-12-22 1999-12-21 Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion

Country Status (11)

Country Link
US (3) US20010055570A1 (de)
EP (1) EP1140044B1 (de)
JP (1) JP2002532542A (de)
AT (1) ATE320247T1 (de)
AU (1) AU3041900A (de)
CA (1) CA2355368A1 (de)
DE (1) DE69930416T2 (de)
ES (1) ES2260952T3 (de)
GB (1) GB9828340D0 (de)
PT (1) PT1140044E (de)
WO (1) WO2000037061A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6919337B2 (en) 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
KR20050056222A (ko) * 2002-09-30 2005-06-14 아쿠스피어 인코포레이티드 흡입용 지속 방출형 다공성 미세입자
KR20080015594A (ko) * 2006-08-16 2008-02-20 주식회사종근당 포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US20110225023A1 (en) * 2010-03-09 2011-09-15 Target Brands, Inc. Prioritized Product Distribution
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4420708A1 (de) * 1994-06-14 1995-12-21 Euro Celtique Sa Entzündungshemmende Zusammensetzung zur Inhalation
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
WO1996028448A1 (en) * 1995-03-10 1996-09-19 Sanofi Winthrop, Inc. 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF
ATE230404T1 (de) * 1995-05-18 2003-01-15 Altana Pharma Ag Cyclohexyldihydrobenzofurane
ATE231501T1 (de) * 1995-05-18 2003-02-15 Altana Pharma Ag Phenyldihydrobenzofurane
DE19541264A1 (de) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EE03523B1 (et) * 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
TW422837B (en) * 1996-05-31 2001-02-21 Mochida Pharm Co Ltd Pyridocarbazole deivatives having cGMP-PDE inhibitory activity
PT937075E (pt) * 1996-11-11 2004-05-31 Altana Pharma Ag Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese
AU5652698A (en) * 1996-11-12 1998-06-03 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
AU739417B2 (en) * 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
AU5704199A (en) * 1998-09-04 2000-03-27 Ortho-Mcneil Pharmaceutical, Inc. 5-heterocyclyl pyrazolo(4,3-d)pyrimidin-7-ones for the treatment of male erectile dysfunction

Also Published As

Publication number Publication date
ATE320247T1 (de) 2006-04-15
ES2260952T3 (es) 2006-11-01
GB9828340D0 (en) 1999-02-17
PT1140044E (pt) 2006-07-31
WO2000037061A3 (en) 2000-10-26
EP1140044B1 (de) 2006-03-15
JP2002532542A (ja) 2002-10-02
US20040214831A1 (en) 2004-10-28
CA2355368A1 (en) 2000-06-29
AU3041900A (en) 2000-07-12
EP1140044A2 (de) 2001-10-10
US20010055570A1 (en) 2001-12-27
US20070197560A1 (en) 2007-08-23
WO2000037061A2 (en) 2000-06-29
DE69930416T2 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
HRP20070534T3 (en) Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CO5271711A1 (es) Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica
RU2007102847A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev
ATE469903T1 (de) Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
WO2004009597A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
IS6288A (is) 5-(2-setnin-5-heterósýklýlsúlfónýlpýrid-3-ýl)díhýdrópýrazóló[4,3-d]pýrimidín-7-ón sem fosfódíesterasa latar
DE69930416D1 (de) Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion
BR9609011A (pt) Composto
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
WO2000012504A3 (de) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on
WO2004021979A3 (en) PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
EP1383769A4 (de) Als cyclinabhängige kinase-inhibitoren geeignete 6-substituierte pyrazolo-3,4-d]pyrimidin-4-one
WO2004106339A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
WO2004092171A3 (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
ATE309246T1 (de) 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate
WO2006127574A3 (en) Method for the treatment of noise phobia in companion animals
IL177856A0 (en) 2-pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
DK0678092T3 (da) 5-alkoxy [1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-thion-forbindelser og anvendelse deraf til fremstilling af 2,2'-dithiobis(5-
ATE377599T1 (de) Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
DK1678182T3 (da) Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
AU4698199A (en) Pyrazolo(1,5-a)triazine corticotropin releasing factor antagonists
TW200635928A (en) 7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine and the use thereof for controlling harmful fungi
TH148526B (th) ไพราโซโลไพริมิดีนชนิดใหม่ (Novel pyrazolopyrimidines) ล่าสุดในฐานะตัวยับยั้งไซคลินดีเพนเดนท์คิเนส (Cyclin dependent kinase inhibitors)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee